secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001759425-26-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026
--------------------------------------------------------------------------------

- 2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).
- 2026 guidance: global net product sales $630-650M, reflecting continued growth.
- Pipeline catalysts: Volixibat VISTAS (PSC) topline Q2 2026; Livmarli EXPAND data Q4 2026; Brelovitug HDV data H2 2026.
- Completed acquisition of Bluejay Therapeutics for brelovitug; raised $268.5M in private placements.
- Cash and investments $391.4M as of Dec 31, 2025; operating expenses $543.4M (incl. $95M non-cash).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/0001759425-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001759425-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer